

HB 344 -- PRESCRIPTION DRUG COSTS

SPONSOR: Kelley (127)

This bill requires health insurance deductible or coinsurance payments for prescription insulin to be calculated at the point of sale based on a price that is reduced by, at a minimum, the amount of rebates received, or to be received, in connection with the dispensing or administration of the drug.

The bill does not require any entity to disclose the actual amount of rebates received on a product, manufacturer, or pharmacy-specific basis and that information is subject to "trade secret" protections.

This bill is similar to HCS HB 2527 (2020) and SB 962 (2020).